Specifically, suppression of the TNF-IRF1-IFNβ-induced secretion of IP-10 and BAFF by tofacitinib might decrease the IP-10-driven recruitment of T cells into the inflamed RA synovium and the BAFF-dependent proliferation, differentiation and antibody production by B cells. Here, IRF1 is linked to rheumatoid arthritis.